Search - tctmd.com

Displaying 1 - 20 of 95

Sort: Relevancy | Date

News Conference News ACC 2026

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

Yael L. Maxwell

March 30, 2026

News Conference News ACC 2026

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Michael O'Riordan

March 29, 2026

News Conference News ACC 2026

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

L.A. McKeown

March 29, 2026

News Conference News ACC 2026

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Yael L. Maxwell

March 29, 2026

Presentation ACC 2026

Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment: The ALL-RISE Randomized Trial

Presenter: Ajay J. Kirtane

March 29, 2026

News Conference News ACC 2026

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

L.A. McKeown

March 28, 2026

News Conference News ACC 2026

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

Michael O'Riordan

March 28, 2026

News Conference News ACC 2026

What’s Going to Be Hot at ACC 2026

Michael O'Riordan

March 20, 2026

News Conference News ACC 2025

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

Yael L. Maxwell

April 07, 2025

News Conference News ACC 2025

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

L.A. McKeown

April 07, 2025

News Conference News ACC 2025

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

Michael O'Riordan

April 04, 2025

News Conference News ACC 2025

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Caitlin E. Cox

March 31, 2025

News Conference News ACC 2025

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

L.A. McKeown

March 30, 2025

News Conference News ACC 2025

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Yael L. Maxwell

March 30, 2025

News Conference News ACC 2025

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

Caitlin E. Cox

March 30, 2025

News Conference News ACC 2024

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

L.A. McKeown

April 08, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

Another Win for TAVI in Low-to-Intermediate Risk Patients

News Conference News ACC 2024

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Yael L. Maxwell

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

Presentation ACC 2024

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Presenter: Jacob Eifer Møller

April 07, 2024

Advertisement

Deferring PCI Until After TAVI Safe, Reduces Bleeding: PRO-TAVI

ORBITA-CTO: PCI Reduces Angina Symptoms in Sham-Controlled Trial

Noninvasive FFR Measures Match Wire-Based Assessment: ALL RISE and FAST III

Impella Support in High-Risk PCI Doesn’t Help, Might Harm: CHIP-BCIS3

Advancing Cath Lab Results with FFRangio Coronary Physiology Assessment: The ALL-RISE Randomized Trial

HI-PEITHO: Catheter-Directed Therapy Bests Anticoagulation in Intermediate-Risk PE

Mechanical Circulatory Support Doesn’t Reduce Infarct Size in STEMI

What’s Going to Be Hot at ACC 2026

AI Shows Promise in Detecting Type 1 MI and Need for Revascularization

EARLY TAVR: Delaying Valve Replacement Increases Risk of Poor Outcomes

DETECT-AS: Alert System Increases AV Replacement in Eligible Patients

PCI Rebounds at 5 Years to Mostly Match CABG: Final FAME 3 Data

Evolut Low Risk Trial: TAVI Holds Up to Surgery at 5 Years

More ALIGN-AR Data Bolster Potential for a Dedicated AR Device

Dapagliflozin Works Well for High-Risk TAVI Patients With HF: DapaTAVI

PREVENT Supports Early PCI for Vulnerable Plaque, With Reductions in MACE

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Another Win for TAVI in Patients at Low-to-Intermediate Risk: DEDICATE-DZHK6

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Percutaneous Transvalvular Micro axial Flow Pump in Infarct Related Cardiogenic Shock

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content